We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Serologicals Corporation Announces UCOE Patent

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Serologicals Corporation has announced that the United States Patent and Trademark Office awarded, on September 27, 2005, patent no. 6,949,361 with respect to its recently acquired artificial ubiquitous chromatin opening element (UCOE) polynucleotide and related vectors.

Serologicals acquired the UCOE gene expression technology, which includes fifty-five issued and pending patents, on September 30, 2005.

UCOEs is designed to improve the yield, consistency and stability of protein production in cultured mammalian cells, allowing simpler and quicker generation of proteins at small scale for drug discovery and research, as well as quicker and easier isolation of stable, highly productive cell lines suitable for larger-scale manufacture of protein therapeutics.

David A. Dodd, President and Chief Executive Officer of Serologicals Corporation, commented on the receipt of the patent, stating, “Our recent acquisition of the UCOE technology exemplifies our ongoing focus on developing and acquiring innovative technologies that ensure we remain the leader in Bioprocessing technologies.”

“Our research and development groups will capitalize on this important technology for the benefit of our customers and will introduce it into our own manufacturing processes.”

“As a result of having applied these technologies, we anticipate supporting our customer's efforts to produce more consistent products with more efficient bioproduction systems.”

Dennis W. Harris, Vice President, Research & Development, Business Development and Chief Scientific Officer for Serologicals Corporation, will be in charge of inquiries about possible out-licensing opportunities using this patented technology.